Alterity Positive Phase 2 Trial Results in Multiple System Atrophy

 – Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –

– Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale –

– Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions –

– ATH434 Demonstrated a Favorable Safety Profile –

– Webcast Held Yesterday with Access to the Recording Below –

The webcast recording can be accessed on the Events and Presentation page of the Company’s website here.

https://www.globenewswire.com/news-release/2025/01/30/3017941/0/en/Alterity-Therapeutics-Announces-Positive-ATH434-Phase-2-Trial-Results-in-Multiple-System-Atrophy-Led-By-Robust-Clinical-Efficacy.html